- Home
- MREO vs CERS Comparison
MREO vs CERS Comparison
Compare MREO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- CERS
- Stock Information
- Founded
- MREO 2015
- CERS 1991
- Country
- MREO United Kingdom
- CERS United States
- Employees
- MREO N/A
- CERS N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- MREO Health Care
- CERS Technology
- Exchange
- MREO Nasdaq
- CERS Nasdaq
- Market Cap
- MREO 281.6M
- CERS 255.0M
- IPO Year
- MREO N/A
- CERS 1997
- Fundamental
- Price
- MREO $1.76
- CERS $1.26
- Analyst Decision
- MREO Strong Buy
- CERS Strong Buy
- Analyst Count
- MREO 5
- CERS 2
- Target Price
- MREO $7.40
- CERS $3.50
- AVG Volume (30 Days)
- MREO 932.9K
- CERS 1.1M
- Earning Date
- MREO 11-11-2025
- CERS 10-29-2025
- Dividend Yield
- MREO N/A
- CERS N/A
- EPS Growth
- MREO N/A
- CERS N/A
- EPS
- MREO N/A
- CERS N/A
- Revenue
- MREO $500,000.00
- CERS $192,510,000.00
- Revenue This Year
- MREO N/A
- CERS $30.03
- Revenue Next Year
- MREO $55.50
- CERS $9.37
- P/E Ratio
- MREO N/A
- CERS N/A
- Revenue Growth
- MREO N/A
- CERS 13.25
- 52 Week Low
- MREO $1.47
- CERS $1.12
- 52 Week High
- MREO $4.72
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- MREO 48.66
- CERS 52.75
- Support Level
- MREO $1.68
- CERS $1.17
- Resistance Level
- MREO $1.88
- CERS $1.35
- Average True Range (ATR)
- MREO 0.07
- CERS 0.05
- MACD
- MREO 0.01
- CERS -0.07
- Stochastic Oscillator
- MREO 45.45
- CERS 92.96
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.